MIRMMirum Pharmaceuticals Inc
MIRM
Mirum Pharmaceuticals Inc1,634
Mkt Cap
$5.33BVolume
896,297.0052W High
$105.7452W Low
$36.88PE Ratio
-119.63MIRM Fundamentals
Price
$102.83Prev Close
$103.10Open
$102.4750D MA
$85.57Beta
0.76Avg. Volume
866,144.10EPS (Annual)
-$1.85P/B
18.12Rev/Employee
$1.05M$2,002.51
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM
TimesSquare Capital Management LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the third quarter, according to the company in its most recent filing with the...
MarketBeat·2d ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company...
MarketBeat·5d ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified...
Business Wire·7d ago
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC
Penserra Capital Management LLC increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 242.4% in the 3rd quarter, according to its most recent disclosure with...
MarketBeat·10d ago
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI (maralixibat) for the treatment of...
Business Wire·12d ago
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI (maralixibat) oral solution and tablet formulation for the...
Business Wire·12d ago
Peter Radovich Sells 2,631 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) COO Peter Radovich sold 2,631 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of...
MarketBeat·14d ago
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 968 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average...
MarketBeat·14d ago
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $940,856.40 in Stock
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 9,108 shares of the business's stock in a transaction on Monday, February 2nd. The stock was sold at an average...
MarketBeat·14d ago
Y Intercept Hong Kong Ltd Takes Position in Mirum Pharmaceuticals, Inc. $MIRM
Y Intercept Hong Kong Ltd purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·14d ago
<
1
2
...
>